Scarica l'app Stockscreener
0.512
2.40%
0.012
Precedente Chiudi:
$0.50
Aprire:
$0.5
Volume 24 ore:
2.31M
Relative Volume:
1.48
Capitalizzazione di mercato:
$6.20M
Reddito:
$1.84M
Utile/perdita netta:
$-17.51M
Rapporto P/E:
-0.3697
EPS:
-1.3849
Flusso di cassa netto:
$-17.30M
1 W Prestazione:
+19.15%
1M Prestazione:
-13.51%
6M Prestazione:
-53.87%
1 anno Prestazione:
-64.69%
Intervallo 1D:
$0.4749
$0.5306
Intervallo di 1 settimana:
$0.4117
$0.5445
Portata 52W:
$0.37
$1.50
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
0.512 | 6.20M | 1.84M | -17.51M | -17.30M | -1.3849 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-08 | Iniziato | ROTH Capital | Buy |
| 2021-07-29 | Iniziato | Aegis Capital | Buy |
| 2020-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2013-12-16 | Iniziato | Oppenheimer | Outperform |
Evogene Ltd Borsa (EVGN) Ultime notizie
Kfir Silberman Pushes for Board Changes at Evogene with 12.61% Stake - TradingView
Evogene (EVGN) investors with 12.61% and 4.13% stakes seek major board changes - Stock Titan
Evogene and Tel Aviv University launch drug discovery initiative - Pharmaceutical Business review -
Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery - Global Agriculture
Evogene and Tel Aviv University team up to speed small-molecule drug discovery - Stock Titan
Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery - marketscreener.com
Evogene Partners with Tel Aviv University on AI Drug... - AllSci
Evogene and Tel Aviv University to accelerate AI-driven small-molecule drug discovery - BioSpectrum Asia
Evogene partners with Tel Aviv University center on drug discovery - Investing.com
Evogene partners with Tel Aviv University center on drug discovery By Investing.com - Investing.com Canada
How Evogene is changing the future for the pharma and agriculture markets - The Jerusalem Post
Why Did EVGN Shares Drop More Than 14% Today? - Stocktwits
Evogene | 6-K: Report of foreign private issuer (related to financial reporting) - Moomoo
Price to book forward of Evogene Ltd. – NASDAQ:EVGN - TradingView
Enterprise value to revenue forward of Evogene Ltd. – NASDAQ:EVGN - TradingView
Evogene Ltd Actuals & Estimates (NASDAQ:EVGN) - TradingView
EVGN Forecast — Price Target — Prediction for 2027 - TradingView
Evogene completes milestone in Google Cloud collaboration By Investing.com - Investing.com South Africa
Evogene completes milestone in Google Cloud collaboration - Investing.com
Evogene Announces Major Milestone in Its Coll - Moomoo
Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization - Nasdaq
Evogene integrates AI agentic systems with Goog... - Pluang
Evogene Ltd (EVGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evogene StockWeekly review and sector context after recent Q1 update - Ad-hoc-news.de
Evogene Ltd (EVGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Evogene Ltd (EVGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Evogene Ltd (EVGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Evogene Ltd (EVGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Evogene Ltd (EVGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Evogene Ltd (EVGN) Institutional Confidence - TradingKey
Evogene Ltd (EVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Evogene Ltd (EVGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
EVGN Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin Amid Weak Operating PerformanceEarnings Cycle Report - dars.gov.et
Evogene Showcases AI-Driven ChemPass Platform and Expanded Google Cloud Collaboration in New Investor Deck - TipRanks
Evogene (EVGN) showcases ChemPass AI drug and ag-chem discovery strategy - Stock Titan
EVGN Q1 2026 Earnings: Deep EPS Miss Raises Investor Concerns Amid Pre-Revenue StageTrough Earnings Signal - newsline.com
Biomica CEO Set to Attend JP Morgan Healthcare Week in San Franc - GuruFocus
Evogene Shares Slip 2.6% as Biotech Stock Tests Key Support Level (EVGN)Flat Correction - newsline.com
Evogene Sets Up $2.9 Million At-the-Market Share Offering With A.G.P. - The Globe and Mail
Evogene enters sales agreement for at-the-market offering of up to $2.93 million - Investing.com Australia
Evogene enters sales agreement for at-the-market offering of up to $2.93 million By Investing.com - Investing.com India
Evogene Ltd. (NASDAQ: EVGN) launches $2.93M ATM program with A.G.P. - Stock Titan
Evogene (EVGN) launches $2.93M at-the-market share offering with A.G.P. - Stock Titan
EVGN Q1 2026 Earnings: Significant EPS Miss Amid Ongoing Operational ChallengesBasic EPS Analysis - newsline.com
Evogene Q1 revenue falls to $0.3 million amid strategic shift - scanx.trade
Full Transcript: Evogene Q1 2026 Earnings CallEvogene (NASDAQ:EVGN) - Benzinga
Evogene to Present Its Pharma Division Achievements at the BIO International Convention - PR Newswire
Earnings Call Summary | Evogene(EVGN.US) Q1 2026 Earnings Conference - 富途牛牛
EVGN Stock Price, Quote & Chart | EVOGENE LTD (NASDAQ:EVGN) - ChartMill
Evogene Reports Positive Phase 1 Data for BMC128 in Cancer - t.co
Evogene completes phase 1 trial of BMC128 cancer treatment By Investing.com - Investing.com South Africa
Evogene Ltd Azioni (EVGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):